Adverse events (AEs) with maintenance olaparib in patients with a germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer (mPaC): Phase III POLO trial.

Michele Reni,Hedy L. Kindler,Pascal Hammel,Eric Van Cutsem,Teresa Macarulla,Michael J. Hall,Joon Oh Park,Daniel Hochhauser,Dirk Arnold,Do-Youn Oh,Anke C. Reinacher-Schick,Giampaolo Tortora,Hana Algül,Eileen Mary O'Reilly,David McGuinness,Karen Cui,Katia Schlienger,Gershon Y. Locker,Talia Golani

ONCOLOGY RESEARCH AND TREATMENT（2020）

引用 0|浏览118

暂无评分

摘要

686Background: In POLO (NCT02184195), maintenance olaparib was well tolerated and led to a significant progression-free survival benefit vs placebo in patients with a gBRCAm and mPaC whose disease ...

查看译文

关键词

metastatic pancreatic cancer,pancreatic cancer,germline brca mutation,maintenance olaparib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要